Regenerative medicine is one of the fastest-growing — and most overhyped — areas of medical tourism. Some applications have strong clinical evidence. Many others don't. This guide separates what's backed by research from what's marketing, and helps you evaluate providers critically.
We approach stem cell therapy differently than other procedures on this site — with deliberate caution. While dental implants and joint replacements have decades of outcome data and standardized protocols, regenerative medicine is still evolving. Some applications are well-supported by clinical evidence. Many are not. And the field is plagued by clinics making unsubstantiated claims to vulnerable patients.
The FDA in the US heavily restricts stem cell therapies — currently, hematopoietic stem cell transplants (bone marrow transplants for blood cancers) and a handful of specific products are FDA-approved. Most other applications are considered investigational. This restriction drives some patients abroad, where regulatory frameworks are more permissive.
More permissive regulation can mean two things: access to legitimate emerging therapies that are further along in clinical trials than the FDA allows domestically, or exposure to unproven treatments sold by clinics exploiting regulatory gaps. The challenge is distinguishing between the two.
Knee osteoarthritis: Multiple RCTs show mesenchymal stem cell (MSC) injections can reduce pain and improve function in mild-to-moderate knee OA, with effects lasting 12–24 months. PRP (platelet-rich plasma) has even more clinical evidence for knee OA.
Bone marrow transplant: Well-established, FDA-approved treatment for blood cancers and certain immune disorders.
Cartilage repair: Autologous chondrocyte implantation (ACI) and some MSC-based cartilage repair protocols have published evidence for specific focal cartilage defects.
Anti-aging IV infusions: No RCT evidence supports systemic IV stem cell infusions for general "anti-aging" or wellness purposes.
Neurological conditions: Stem cell treatments for MS, Parkinson's, autism, and spinal cord injury remain experimental. Some early-phase trials show promise, but commercial clinics offering these treatments are getting ahead of the science.
COPD/lung conditions: Clinics marketing stem cells for lung conditions lack supporting RCT evidence.
Erectile dysfunction: Limited early data; no established clinical protocols. Marketing far exceeds evidence.
| Treatment | United States | Colombia | Mexico | Evidence Level |
|---|---|---|---|---|
| PRP Injection (single joint) | $500–$2,000 | $150–$500 | $200–$600 | Moderate (RCTs exist) |
| MSC Injection (single joint) | $5,000–$15,000 | $2,000–$5,000 | $1,500–$5,000 | Moderate (RCTs exist for knee OA) |
| MSC (multiple joints) | $10,000–$30,000 | $4,000–$8,500 | $3,000–$10,000 | Moderate |
| IV Stem Cell Infusion | $5,000–$25,000 | $3,000–$8,000 | $2,000–$8,000 | Weak (no RCT support for most claims) |
| Exosome Therapy | $3,000–$10,000 | $1,500–$5,000 | $1,500–$5,000 | Very early (mostly preclinical) |
Understanding why stem cell therapy availability differs by country is essential to making informed decisions.
United States (FDA): The FDA classifies most stem cell products as biologics requiring full clinical trial approval before commercial use. This means only a handful of specific applications are legally marketed. The FDA has taken enforcement action against clinics offering unapproved stem cell treatments domestically. This conservative approach protects patients from unproven treatments but also restricts access to emerging therapies that may have clinical merit.
Colombia (INVIMA): Colombia's health regulatory agency allows certain stem cell applications under a more permissive framework than the FDA. University-affiliated clinics in Medellín and Bogotá operate stem cell programs under INVIMA oversight, primarily for orthopedic applications. Colombia is emerging as a hub for regenerative medicine tourism, with some clinics conducting their own clinical research. The regulatory environment is more flexible but still requires institutional oversight.
Mexico (COFEPRIS): Mexico's regulatory environment has historically been permissive toward stem cell clinics, particularly in border cities. This has attracted both legitimate clinical programs and opportunistic operations. COFEPRIS has been tightening oversight, but enforcement remains inconsistent. Exercise heightened due diligence when evaluating stem cell providers in Mexico.
Panama: Panama has established a framework for autologous stem cell therapies and is home to several established regenerative medicine clinics. The regulatory approach falls between the FDA's strict model and Mexico's more open one.
Any clinic claiming stem cells can cure Alzheimer's, autism, MS, COPD, or other complex conditions is making claims that exceed published evidence. Legitimate providers discuss treatment as experimental or emerging, not curative.
A credible stem cell clinic should be able to cite published studies supporting their specific protocol — not just "stem cells in general." If they can't point to peer-reviewed evidence for the exact treatment they're offering, proceed with extreme caution.
Clinics that offer the same stem cell protocol for knee pain, lung disease, neurological conditions, and anti-aging are a major red flag. Different conditions require different cell types, delivery methods, and dosing — a one-size-fits-all approach is not science.
"Limited spots," "special pricing this week," and urgency-driven sales are marketing tactics, not medical practice. A legitimate clinic will give you time to review, get second opinions, and make an informed decision.
Standalone stem cell clinics with no university or hospital affiliation, no IRB oversight, and no published research output should be approached with skepticism. The best regenerative medicine programs operate within or alongside academic medical institutions.
Patient testimonials and celebrity endorsements are not clinical evidence. Ask for published data — case series at minimum, RCTs ideally. If the only "evidence" is video testimonials on the clinic's website, that tells you where their investment goes: marketing, not research.
If you're considering stem cell therapy abroad — particularly for orthopedic applications where evidence is moderate — use these criteria to evaluate providers:
1. Published research. Does the clinic or its physicians have peer-reviewed publications? Not blog posts or press releases — actual papers in indexed journals. PubMed-searchable publications from the treating physician are the strongest signal.
2. Institutional affiliation. Is the clinic affiliated with a university, research hospital, or recognized medical institution? University-affiliated programs have IRB (ethics board) oversight, which means their protocols have been reviewed for patient safety.
3. Cell source and processing. Where do the stem cells come from? Autologous (your own tissue — bone marrow or adipose) is generally safer than allogeneic (donor cells). How are cells processed? Is the lab GMP (Good Manufacturing Practice) certified? Are cell counts verified before injection?
4. Condition-specific protocol. Does the clinic have a specific, published protocol for your condition? Or are they offering a generic stem cell product for everything? Specific protocols indicate clinical rigor.
5. Honest communication about limitations. A legitimate provider will tell you: this is what the evidence shows, this is what we don't know yet, and these are the realistic expectations for your specific case. If everything sounds too certain and too positive, that's a red flag.
6. Follow-up and outcome tracking. Does the clinic track patient outcomes systematically? Do they follow up at 3, 6, and 12 months? Clinics that don't track outcomes aren't doing science — they're selling a service.
For knee osteoarthritis specifically, there is moderate clinical evidence supporting MSC and PRP injections — multiple RCTs show pain reduction and functional improvement lasting 12–24 months. If you've exhausted conservative treatments (physical therapy, cortisone injections, hyaluronic acid) and aren't ready for joint replacement, stem cell therapy at a reputable, research-backed clinic abroad is a reasonable option to explore. It's not a cure for arthritis, but it may delay the need for replacement surgery.
The FDA's regulatory framework requires full clinical trial approval before commercial marketing of biological products, which takes years and hundreds of millions of dollars. Other countries have regulatory frameworks that allow certain stem cell applications under institutional oversight without requiring the same level of completed trials. Neither approach is inherently right or wrong — the FDA's caution protects against unproven treatments, while other frameworks provide earlier access to emerging therapies.
For most marketed conditions (anti-aging, general wellness, neurological conditions), IV stem cell infusions lack RCT evidence. The cells are injected systemically and there is limited evidence they reach or benefit specific target tissues. For most patients, the $3,000–$8,000 cost is not justified by current evidence. Targeted injections (directly into an affected joint, for example) have stronger supporting data than systemic IV infusions.
Colombia's INVIMA regulatory framework allows certain stem cell applications that the FDA restricts, and the country has university-affiliated clinics (particularly in Medellín) conducting clinical research in regenerative medicine. Colombia's medical infrastructure, favorable cost structure, proximity to the US, and established medical tourism ecosystem make it a natural hub. That said, not every stem cell clinic in Colombia is university-affiliated or research-backed — apply the same vetting criteria described above.